New Leadership at Climb Bio, Inc.
WELLESLEY, Mass. — Climb Bio, Inc. (NASDAQ: CLYM) has made an exciting announcement regarding its leadership team. The company is pleased to welcome Douglas E. Williams, Ph.D., as the new Chair of its Board of Directors. Dr. Williams takes over from Andrew Levin, who will continue to contribute to the board as a director. Liam Ratcliffe will be stepping down from his director role, making way for Dr. Williams to lead.
Expertise in Biotechnology
With more than 30 years of executive experience in the biotechnology industry, Dr. Williams brings a wealth of knowledge to Climb Bio. His career has been marked by pivotal leadership roles in research and development, culminating in the significant contributions he has made to breakthrough drugs like Leukine®, Enbrel®, Adcetris®, Tecfidera®, Alprolix®, Eloctate®, and Spinraza®. Dr. Williams is not only an accomplished leader but has also celebrated a remarkable tenure as a CEO, helping both private and public entities navigate from the developmental stages to full commercialization and overseeing successful mergers.
Insights from the President
Aoife Brennan, the President and CEO of Climb Bio, expressed her enthusiasm for Dr. Williams' appointment. “I am thrilled to welcome Dr. Doug Williams to Climb Bio. His experience and leadership in biotechnology and pharmaceuticals will provide invaluable perspectives as we continue to grow the company,” she stated. “Specifically, his expertise in drug development is timely as we aim to improve treatments for the approximately 50 million patients battling immune-mediated diseases, both in the U.S. and worldwide.”
Dr. Williams’ Impressive Background
Before joining Climb Bio, Dr. Williams held significant roles, including President of Research and Development at Sana Biotechnology and CEO of Codiak BioSciences. Additionally, he served as Executive Vice President at Biogen, where he played a critical role in shaping the future of the company. His leadership experience also includes serving as CEO at ZymoGenetics, which was acquired by Bristol Myers Squibb, and holding several prestigious positions, such as Chief Scientific Officer at Seattle Genetics.
Commitment to Climb Bio's Mission
In his new role, Dr. Williams expressed his excitement, stating, “I am honored to join Climb Bio at this pivotal moment. As we advance budoprutug, I am confident in its potential to treat a wide array of B-cell mediated diseases. I look forward to collaborating with our talented team to bring forth innovative therapeutics to patients in need.”
A Positive Transition
Andrew Levin, the outgoing Chair, commended Dr. Williams' exceptional track record in the biotechnology sector, stating, “During this transformative time after acquiring Tenet Medicines, we have made significant strides. I am proud to pass the torch to Doug, whose extensive experience will be crucial in steering Climb Bio towards achieving its goals while I stay on board.” He extended gratitude to Liam Ratcliffe for his contributions during their collective journey.
About Climb Bio, Inc.
Climb Bio, Inc. is a forward-thinking, clinical-stage biotechnology company dedicated to developing therapeutics for immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has shown promise in B-cell depletion, potentially benefiting a range of B-cell mediated conditions.
Frequently Asked Questions
Who is the new Chair of Climb Bio?
The new Chair of Climb Bio's Board is Douglas E. Williams, Ph.D., who brings extensive experience in biotechnology.
What is Dr. Williams' background?
Dr. Williams has over 30 years of experience, having held senior roles in leading biotechnology firms and contributed to numerous successful drug developments.
What are the primary goals of Climb Bio?
Climb Bio aims to develop effective therapeutics for patients suffering from immune-mediated diseases, focusing on innovative treatments like budoprutug.
What position did Andrew Levin hold?
Andrew Levin was the Chair of the Board before transitioning to a director role and continues to support Climb Bio's initiatives.
How does budoprutug work?
Budoprutug is an anti-CD19 monoclonal antibody designed to deplete B-cells, potentially aiding in the treatment of various B-cell mediated diseases.
